Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

1708 ARTÍCULOS , VIENDO DEL 1246 AL 1260

Inflammatory biomarkers in Alzheimer's disease plasma

Morgan AR, Touchard S, Leckey C, O'Hagan C, Nevado-Holgado AJ; NIMA Consortium; Barkhof F, Bertram L, Blin O, Bos I, Dobricic V, Engelborghs S, Frisoni G, Frölich L, Gabel S, Johannsen P, Kettunen P, Kłoszewska I, Legido-Quigley C, Lleó A, Martinez-Lage P, Mecocci P, Meersmans K, Molinuevo JL, Peyratout G, Popp J, Richardson J, Sala I, Scheltens P, Streffer J, Soininen H, Tainta-Cuezva M, Teunissen C, Tsolaki M, Vandenberghe R, Visser PJ, Vos S, Wahlund LO, Wallin A, Westwood S, Zetterberg H, Lovestone S, Morgan BP; Annex: NIMA–Wellcome Trust Consortium for Neuroimmunology of Mood Disorders and Alzheimer's Disease.

Alzheimers Dement. 2019 Jun;15(6):776-787. doi: 10.1016/j.jalz.2019.03.007. Epub 2019 Apr 30.

Exosomes in Pathogenesis, Diagnosis, and Treatment of Alzheimer's Disease

Jiang L, Dong H, Cao H, Ji X, Luan S, Liu J.

Med Sci Monit. 2019 May 6;25:3329-3335. doi: 10.12659/MSM.914027.

Advancing Alzheimer's Disease Treatment: Lessons from CTAD 2018

Vellas B, Bain LJ, Touchon J, Aisen PS.

J Prev Alzheimers Dis. 2019;6(3):198-203. doi: 10.14283/jpad.2019.11.

Plasma Biomarkers: Potent Screeners of Alzheimer's Disease

Naveed M, Mubeen S, Khan A, Ibrahim S, Meer B.

Am J Alzheimers Dis Other Demen. 2019 Aug;34(5):290-301. doi: 10.1177/1533317519848239. Epub 2019 May 9.

Diagnosis of Alzheimer's disease utilizing amyloid and tau as fluid biomarkers

Lee JC, Kim SJ, Hong S, Kim Y.

Exp Mol Med. 2019 May 9;51(5):1-10. doi: 10.1038/s12276-019-0250-2.

Biomarker profiles of Alzheimer's disease and dynamic of the association between cerebrospinal fluid levels of β-amyloid peptide and tau

Lafirdeen ASM, Cognat E, Sabia S, Hourregue C, Lilamand M, Dugravot A, Bouaziz-Amar E, Laplanche JL, Hugon J, Singh-Manoux A, Paquet C, Dumurgier J.

PLoS One. 2019 May 14;14(5):e0217026. doi: 10.1371/journal.pone.0217026. eCollection 2019.

CSF neurogranin as a neuronal damage marker in CJD: a comparative study with AD

Blennow K, Diaz-Lucena D, Zetterberg H, Villar-Pique A, Karch A, Vidal E, Hermann P, Schmitz M, Ferrer Abizanda I, Zerr I, Llorens F.

J Neurol Neurosurg Psychiatry. 2019 Aug;90(8):846-853. doi: 10.1136/jnnp-2018-320155. Epub 2019 May 16.

Definition and quantification of six immune- and neuroregulatory serum proteins in healthy and demented elderly

Schipke CG, Günter O, Weinert C, Scotton P, Sigle JP, Kallarackal J, Kabelitz D, Finzen A, Feuerhelm-Heidl A.

Neurodegener Dis Manag. 2019 Aug;9(4):193-203. doi: 10.2217/nmt-2019-0003. Epub 2019 May 17.

Biomarkers for Alzheimer's Disease

Guzman-Martinez L, Maccioni RB, Farías GA, Fuentes P, Navarrete LP.

Curr Alzheimer Res. 2019;16(6):518-528. doi: 10.2174/1567205016666190517121140.

Alzheimer's disease: Making the point

Bernardini S, Zima T.

Clin Biochem. 2019 Oct;72:1-2. doi: 10.1016/j.clinbiochem.2019.05.007. Epub 2019 May 21.

Associations of AD Biomarkers and Cognitive Performance with Nutritional Status: The NUDAD Project

Doorduijn AS, Visser M, van de Rest O, Kester MI, de Leeuw FA, Boesveldt S, Fieldhouse JLP, van den Heuvel EGHM, Teunissen CE, Scheltens P, van der Flier WM, de van der Schueren MAE.

Nutrients. 2019 May 23;11(5):1161. doi: 10.3390/nu11051161.

A Comparative Analysis of the Treatment of Decision-Making by or for Patients with Neurodegenerative Diseases in Four Legal Jurisdictions

Guzik-Makaruk EM, Pływaczewski EW, Laskowska K, Filipkowski W, Jurgielewicz-Delegacz E, Mroczko P.

J Alzheimers Dis. 2019;70(1):1-10. doi: 10.3233/JAD-190259.

What is the clinical impact of cerebrospinal fluid biomarkers on final diagnosis and management in patients with mild cognitive impairment in clinical practice? Results from a nation-wide prospective survey in France

Cognat E, Mouton Liger F, Troussière AC, Wallon D, Dumurgier J, Magnin E, Duron E, Gabelle A, Croisile B, de la Sayette V, Jager A, Blanc F, Bouaziz-Amar E, Miguet-Alfonsi C, Quillard M, Schraen S, Philippi N, Beaufils E, Pasquier F, Hannequin D, Robert P, Hugon J, Paquet C; ePLM network.

BMJ Open. 2019 May 30;9(5):e026380. doi: 10.1136/bmjopen-2018-026380.

Target engagement in an alzheimer trial: Crenezumab lowers amyloid β oligomers in cerebrospinal fluid

Yang T, Dang Y, Ostaszewski B, Mengel D, Steffen V, Rabe C, Bittner T, Walsh DM, Selkoe DJ.

Ann Neurol. 2019 Aug;86(2):215-224. doi: 10.1002/ana.25513. Epub 2019 Jun 22.

Neuroimaging Biomarkers for Alzheimer's Disease

Márquez F, Yassa MA.

Mol Neurodegener. 2019 Jun 7;14(1):21. doi: 10.1186/s13024-019-0325-5.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias